List of Excipients in Branded Drug NEXPLANON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Organon USA Inc	NEXPLANON	etonogestrel	0052-4330	BARIUM SULFATE	2029-01-16
Organon USA Inc	NEXPLANON	etonogestrel	0052-4330	ETHYLENE-VINYL ACETATE COPOLYMER	2029-01-16
Organon USA Inc	NEXPLANON	etonogestrel	0052-4330	MAGNESIUM STEARATE	2029-01-16
Organon LLC	NEXPLANON	etonogestrel	78206-145	BARIUM SULFATE	2029-01-16
Organon LLC	NEXPLANON	etonogestrel	78206-145	ETHYLENE-VINYL ACETATE COPOLYMER	2029-01-16

Nexplanon Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Nexplanon is an etonogestrel-releasing subdermal implant with a simple excipient system but significant manufacturing and device-combination barriers. The commercial opportunity is stronger in excipient qualification, radiopaque polymer supply, implant extrusion, applicator technology, and regional licensing than in conventional formulation substitution.

The implant contains 68 mg of etonogestrel in an ethylene-vinyl acetate copolymer matrix, with barium sulfate for radiopacity and magnesium stearate as an additional inactive component. Organon markets Nexplanon in the United States, where the product is approved for pregnancy prevention for up to five years.[1] The product is a drug-device combination because the implant is supplied with a dedicated sterile applicator.

What excipients are used in Nexplanon?

Nexplanon uses three principal formulation excipients:

Component	Function	Commercial relevance
Etonogestrel	Active pharmaceutical ingredient	Synthetic progestin released over time
Ethylene-vinyl acetate copolymer	Matrix-forming polymer and release-control excipient	Critical to drug diffusion, mechanical strength, extrusion, and long-term stability
Barium sulfate	Radiopaque excipient	Enables visualization by X-ray and supports localization and removal
Magnesium stearate	Processing and lubrication aid	Supports manufacture of the implant matrix

The Nexplanon implant is a single flexible rod measuring approximately 4 cm in length and 2 mm in diameter. It contains no reservoir membrane. Drug release occurs through diffusion from the polymer matrix.[1]

The applicator and implant should be analyzed separately. The applicator is not an excipient, but it is central to the product’s regulatory status, usability, and competitive barriers.

Why is ethylene-vinyl acetate important?

Ethylene-vinyl acetate, or EVA, controls the physical and release properties of the implant. Relevant variables include:

• Vinyl acetate content
• Polymer molecular weight
• Melt-flow behavior
• Crystallinity
• Residual monomers and solvents
• Particle size and dispersion of etonogestrel
• Mixing temperature and residence time
• Extrusion conditions
• Surface finish and dimensional tolerance

A change in EVA grade can alter etonogestrel release, implant stiffness, insertion force, dimensional stability, sterilization performance, and shelf life. For a long-acting implant, the excipient is part of the drug-delivery technology rather than an interchangeable bulking material.

A competing manufacturer would therefore need to qualify the polymer at the grade and supplier level. A pharmacopeial name alone would not establish equivalence.

What role does barium sulfate play?

Barium sulfate makes the implant radiopaque. Radiopacity enables clinicians to locate the implant using X-ray-based imaging when the rod is difficult to palpate or appears to have migrated.

The commercial value of barium sulfate is functional rather than pharmacological. Its performance depends on:

• Particle-size distribution
• Purity and heavy-metal controls
• Dispersion within EVA
• Loading level
• Impact on mechanical strength
• Impact on etonogestrel diffusion
• Imaging visibility after sterilization and aging

A substitute radiopaque agent could create a new product opportunity, but it would require comparative imaging, mechanical, extractables, drug-release, toxicology, and stability data. A substitute would not be a routine excipient change.

How does Nexplanon’s excipient system affect product performance?

Nexplanon’s performance is determined by the interaction between the active ingredient, polymer matrix, radiopaque filler, and manufacturing process.

Drug-release control

The release profile must maintain effective etonogestrel exposure over the labeled duration. Key formulation risks include:

• Initial burst release
• Declining release below the therapeutic target
• Batch-to-batch variability
• Drug crystallization or agglomeration
• Polymer aging
• Sterilization-induced changes
• Altered diffusion caused by barium sulfate loading

For generic or follow-on development, release testing is likely to be a major comparability requirement. A product can match the nominal dose and still fail to match the reference product’s release behavior.

Mechanical and insertion performance

The rod must be flexible enough for insertion and removal but mechanically stable enough to resist fracture or deformation. EVA selection influences:

• Rod flexibility
• Compression and tensile strength
• Resistance to cracking
• Surface defects
• Insertion force
• Removal behavior

The finished implant must also remain compatible with the applicator. A formulation that improves release but changes rod stiffness can create a device-performance failure.

Sterilization and packaging

The sterilization method must preserve the polymer, active ingredient, applicator, and packaging system. Relevant controls include:

• Sterility assurance
• Ethylene oxide residuals, if applicable
• Moisture and oxygen exposure
• Package integrity
• Long-term dimensional stability
• Drug potency and related substances
• Polymer degradation

Packaging suppliers with validated sterile-barrier systems can create a commercial entry point even where formulation substitution is difficult.

What formulation patents protect Nexplanon?

Nexplanon’s commercially relevant protection is broader than a single excipient claim. Potential protection categories include:

1. Etonogestrel implant compositions.
2. EVA matrix systems for controlled steroid release.
3. Radiopaque contraceptive implants.
4. Implant dimensions and drug loading.
5. Implant manufacturing and extrusion methods.
6. Applicator and insertion systems.
7. Implant localization and removal-related technology.
8. Packaging, sterilization, and combination-product configurations.

The earliest Implanon and Nexplanon patent families were filed decades ago. Many foundational U.S. patent terms have expired or approached expiration based on their priority dates and statutory patent terms. Current freedom-to-operate analysis must rely on the live claims in the relevant jurisdiction, including continuation patents, terminal disclaimers, patent-term adjustment, pediatric exclusivity, and non-U.S. rights.

The FDA Orange Book is the principal U.S. source for patents and regulatory exclusivity associated with an approved drug application.[2] A supplier should not assume that the expiration of a foundational implant patent eliminates risk from later applicator, manufacturing, or formulation claims.

When does Nexplanon lose exclusivity?

Nexplanon has already moved beyond its primary market-exclusivity period. The product was approved by the FDA in 2006 as Implanon and later received the Nexplanon name and radiopaque configuration in the United States.[1,3]

The main commercial barriers are now likely to be:

• Complex product development
• Clinical and pharmacokinetic comparability
• Implant release matching
• Applicator replication
• Sterility validation
• Manufacturing scale-up
• Provider adoption
• State and country-specific procurement
• Patent claims that remain enforceable in particular markets

Nexplanon is not a biologic, so biosimilar rules do not apply. A follow-on product would be treated as a complex small-molecule implant and drug-device combination rather than as a biosimilar.

What is the Orange Book status of Nexplanon?

The Orange Book identifies approved products, therapeutic-equivalence information, patent listings, and certain regulatory exclusivity data. Nexplanon is listed under Organon’s U.S. NDA 021529.[2]

The relevant regulatory analysis should distinguish:

• FDA approval status
• Orange Book patent listings
• Hatch-Waxman exclusivity
• Patent expiration
• Device-related intellectual property
• State substitution rules
• Foreign regulatory protection

An ANDA applicant would need to address listed patents through the applicable certification process. A Paragraph IV certification could trigger patent litigation and a 30-month stay if the statutory conditions are met. Because Nexplanon is a long-acting implant with a dedicated applicator, the applicant may also face product-specific FDA requirements that are not captured by a standard oral-solid-dose generic model.

Which companies are challenging Nexplanon?

No broad U.S. generic competitive field comparable to oral contraceptives has emerged around Nexplanon. The product’s principal commercial competition comes from alternative long-acting reversible contraceptives, including:

• Levonorgestrel intrauterine systems
• Copper intrauterine devices
• Depot medroxyprogesterone acetate
• Combined hormonal contraceptives
• Permanent contraception
• Other implant technologies outside the U.S. market

A direct follow-on implant would likely require a dedicated development program. The absence of a large direct-generic market does not prove that patent barriers remain decisive. It indicates that technical execution, regulatory cost, manufacturing scale, and provider-channel access may be more important than the active ingredient itself.

What generic entry risks exist for Nexplanon?

Generic entry would have to address five major risks.

1. Pharmaceutical equivalence

The follow-on product would need the same active ingredient, dose, route, dosage form, and essential performance characteristics. Etonogestrel is commercially available as an active ingredient, but implant-grade drug substance must meet additional particle, purity, and stability requirements.

2. In vitro release equivalence

The applicant would need a robust method to compare release against Nexplanon. Standard dissolution methods for tablets are not directly applicable. A validated in vitro release method would need to control temperature, media, agitation, sink conditions, sampling, and analytical recovery.

3. In vivo pharmacokinetic comparability

A follow-on implant may require comparative pharmacokinetic data. The study design would need to account for the long release period, early exposure phase, hormonal suppression, body-mass effects, and implant insertion and removal procedures.

4. Applicator equivalence

The applicator affects insertion depth, rod placement, user handling, needlestick risk, and deployment reliability. A technically equivalent implant paired with a materially different applicator could require separate human-factors and device validation.

5. Sterile manufacturing

The product requires reproducible micro-extrusion or equivalent processing, cleanroom controls, sterilization validation, and packaging integrity. These requirements create a higher fixed-cost barrier than a conventional oral generic.

What excipient strategies could support commercial entry?

Strategy 1: Become a qualified EVA supplier

A polymer producer could target pharmaceutical-grade EVA for long-acting implants. The opportunity depends on:

• Consistent vinyl acetate content
• Tight molecular-weight distribution
• Low extractables
• Reliable supply
• Change-control discipline
• Regulatory documentation
• Technical support for extrusion

The supplier would need to support regulatory filings with detailed composition, manufacturing, impurity, and stability data.

Strategy 2: Supply radiopaque implant materials

Barium sulfate suppliers can differentiate through controlled particle size, low impurity levels, dispersion quality, and documentation designed for implantable products.

A higher-value offering would combine barium sulfate with a validated compounding package for EVA and etonogestrel. This would reduce development work for implant manufacturers.

Strategy 3: Develop alternative radiopaque excipients

Alternative radiopaque materials could improve imaging, reduce density, or support new implant geometries. Candidates would require a full toxicological and performance assessment. The opportunity is technically attractive but regulatory-intensive because the radiopaque excipient affects both device functionality and drug release.

Strategy 4: Improve processability

A formulation platform could target:

• Lower extrusion temperature
• Reduced drug degradation
• Improved dispersion
• Lower insertion force
• Better surface uniformity
• Reduced manufacturing scrap
• Shorter cycle times

Process improvements may provide more practical commercial value than replacing the established excipients.

Strategy 5: Develop next-generation implants

A new implant could use the Nexplanon excipient system while adding:

• Longer duration
• Smaller diameter
• Easier removal
• Improved imaging
• Adjustable release
• A redesigned applicator
• Reduced insertion pain
• Alternative progestins

Such products would generally require a new regulatory strategy and may not qualify as simple generics. They could, however, support new composition, method-of-use, device, and manufacturing patent families.

How does Nexplanon compare with IUD commercial opportunities?

Nexplanon competes with intrauterine devices but has a different technical and commercial profile.

Factor	Nexplanon	Hormonal IUD	Copper IUD
Primary active	Etonogestrel	Levonorgestrel	None
Delivery site	Subdermal arm	Uterus	Uterus
Core release technology	EVA matrix implant	Polymer or reservoir-based IUD system	Copper-bearing device
Radiopacity requirement	Important	Important	Important
Dedicated applicator	Yes	Yes	Yes
Main formulation barrier	Long-term steroid diffusion through EVA	Hormone reservoir or matrix release	Copper geometry and surface control
Main manufacturing barrier	Micro-extrusion, sterilization, applicator integration	Molding, assembly, drug loading, sterilization	Device assembly and material consistency

Nexplanon has a relatively simple implant composition but a difficult manufacturing and delivery system. Hormonal IUDs have more complex device geometries and may have broader formulation and assembly claims.

What licensing opportunities exist around Nexplanon technology?

Commercial licensing opportunities may arise in four areas:

1. Regional commercialization of etonogestrel implants outside markets directly supplied by Organon.
2. Contract manufacturing for implant rods, applicators, sterile packaging, or final assembly.
3. Excipient and polymer supply agreements with regulatory support.
4. Licensing of next-generation implant and insertion technologies.

An agreement should address ownership of process improvements, supplier qualification, change control, territorial rights, regulatory responsibility, minimum purchase commitments, and access to reference-product data.

Publicly disclosed licensing information should be distinguished from private supply and manufacturing agreements. Organon’s public filings identify Nexplanon as a commercial product but do not provide a complete map of every excipient, manufacturing, or regional technology agreement.[4]

What is the revenue exposure of Nexplanon?

Nexplanon is a significant branded contraceptive product for Organon, but the company reports commercial performance within broader product and geographic reporting categories. Product-level public disclosure may not provide a complete global revenue figure for every reporting period.[4]

Revenue exposure depends on:

• U.S. public-sector contraception contracts
• Commercial payer coverage
• Provider reimbursement
• Global tender activity
• Duration extension from three to five years
• Manufacturing capacity
• Competitor entry
• Reimbursement for insertion and removal

The five-year labeled duration can reduce annual replacement frequency while improving product value per implant. A direct competitor could pressure price, contract access, and provider loyalty even without immediate substitution across the entire contraceptive market.

How strong is the Nexplanon patent estate?

The patent estate is strongest where claims cover the integrated product rather than a basic ingredient. A claim directed only to etonogestrel or a conventional EVA matrix is more vulnerable after foundational patent expiry. Claims covering a specific radiopaque implant, release profile, applicator, insertion method, or manufacturing process can remain commercially relevant for longer.

The estate should be scored across:

Category	Relative risk or strength
Etonogestrel composition	Low to moderate after foundational expiry
EVA matrix concept	Low to moderate
Specific drug-polymer ratios and dimensions	Moderate
Radiopaque formulation	Moderate
Implant extrusion process	Moderate to high if narrowly claimed
Applicator design	Moderate to high
Sterile combination product	Moderate
Manufacturing know-how	High practical value even without patent protection

Trade secrets can be as important as patents. Extrusion parameters, mixing order, dispersion controls, in-process testing, and applicator assembly tolerances may not be visible in public patent documents.

What is the FDA regulatory status of Nexplanon?

Nexplanon is FDA-approved for contraception and is supplied as an implant with an applicator. The FDA label identifies etonogestrel as the active ingredient and describes the EVA-based implant, radiopaque barium sulfate, and magnesium stearate.[1]

A follow-on developer should expect interaction with FDA divisions responsible for both drug and device considerations. The development program would likely address:

• Active ingredient characterization
• Excipient qualification
• Implant dimensions
• In vitro release
• Pharmacokinetics
• Sterility
• Packaging
• Applicator performance
• Human factors
• Biocompatibility
• Removal and insertion procedures
• Labeling and training

Key Takeaways

• Nexplanon uses etonogestrel in an EVA matrix with barium sulfate and magnesium stearate.
• EVA is the critical excipient because it controls release, flexibility, extrusion, and stability.
• Barium sulfate is a functional radiopaque excipient and can affect both imaging and drug diffusion.
• Nexplanon is a drug-device combination, so generic development requires an implant and applicator strategy.
• Biosimilar rules do not apply because etonogestrel is a small molecule.
• Foundational patent protection is old, but later formulation, process, applicator, and manufacturing claims require jurisdiction-specific review.
• The strongest commercial opportunities are qualified polymer supply, radiopaque excipient systems, contract manufacturing, sterile packaging, and next-generation implants.
• The main barriers to generic entry are release comparability, sterile extrusion, applicator equivalence, and provider-channel access.

FAQs

Can a different polymer replace EVA in a Nexplanon follow-on product?

Yes, technically, but a different polymer would create a new release, mechanical, stability, and biocompatibility profile. It would require substantial comparative and regulatory data.

Is barium sulfate in Nexplanon a patentable commercial opportunity?

Barium sulfate itself is established and widely used. Commercial value would more likely arise from controlled particle characteristics, dispersion technology, implant-specific qualification, or a new radiopaque formulation.

Does Nexplanon require a biosimilar application?

No. Nexplanon contains etonogestrel, a small-molecule steroid, and is not regulated through the biosimilar pathway.

Can an excipient supplier sell directly into the Nexplanon market?

An excipient supplier can target follow-on manufacturers, contract manufacturers, or new implant developers. Direct supply into Organon’s product would require customer qualification and commercial contracting.

What is the most attractive next-generation Nexplanon opportunity?

A smaller, easier-to-remove implant with improved radiopacity, lower insertion force, and validated long-duration release is likely to offer greater differentiation than a simple excipient substitution.

References

1. U.S. Food and Drug Administration. (2024). Nexplanon (etonogestrel implant) prescribing information. Organon & Co.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2006). FDA approves Implanon contraceptive implant. https://www.fda.gov/

4. Organon & Co. (2024). Annual report and Form 10-K. U.S. Securities and Exchange Commission.